All In MedTech

Device Trial Radar · NCT06541795

Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses

Evaluation of Long-term Safety and Performance of AcrySof IQ Vivity Extended Vision and AcrySof IQ Vivity Toric Extended Vision Intraocular Lenses

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Alcon ResearchNot on our public-company list
Sponsor type
Industry
First posted
Aug 7, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this post-market study is to describe the long-term safety and performance of AcrySof IQ Vivity and AcrySof IQ Vivity Toric intraocular lens (IOL) models in a real-world setting through routine clinical practice.

Conditions

  • Aphakia
  • Presbyopia
  • Residual Refractive Cylinder

Interventions

  • AcrySof IQ Vivity Extended Vision IOLDevice

    UV-absorbing, with or without blue light filtering, foldable IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients from whom a cataractous lens has been removed. The IOL mitigates the effects of presbyopia by providing an extended depth of focus. The toric models in addition reduce residual refractive astigmatism in patients with pre-existing corneal astigmatism.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Binocular Best Corrected Distance Visual Acuity (BCDVA) at Visit 1Time frame: Visit 1, Year 3-5 postoperative
  2. Incidence of adverse eventsTime frame: Up to Year 3-5 postoperative
  3. Incidence of device deficienciesTime frame: Up to Year 3-5 postoperative

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Call Center for Trial Locations

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.